Stay updated on Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.9%
    Check dated 2025-06-20T04:48:48.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.1%
    Check dated 2025-06-13T00:51:30.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T20:49:55.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an opportunity for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T15:39:37.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The page has removed two significant clinical trial references related to Nivolumab and Ipilimumab, which may impact the availability of key information on these treatments for metastatic urothelial carcinoma and recurrent small-cell lung cancer.
    Difference
    1.0%
    Check dated 2025-05-15T07:15:53.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    The page has removed two significant studies related to the efficacy and safety of Nivolumab in treating metastatic esophagogastric cancer and recurrent metastatic urothelial carcinoma, which may impact the information available to readers about these treatments.
    Difference
    0.7%
    Check dated 2025-05-08T05:28:20.000Z thumbnail image

Stay in the know with updates to Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial page.